Resolvins RvD1 and 17R RvD1 alleviate signs of inflammation in a rat model of endometriosis

RvD1 and 17(R)-RvD1 reduced cyst vascular permeability and associated vaginal hyperalgesia in rats with surgically-induced endometriosis suggesting that further investigation of therapeutic anti-inflammatory potentials of resolvins can be considered.


Natalia Dmitrieva, Ph.D., Gregory Suess, B.S., Russell Shirley, B.S.

Volume 102, Issue 4, Pages 1191-1197



To study the effects of two resolvins of D series, RvD1 and 17(R)-RvD1, on inflammatory signs associated with endometriosis (ENDO).


In vivo research study.


Research laboratory.


Female Sprague-Dawley rats.


Intravenous or intraperitoneal injections of RvD1 (300 ng/kg) or 17(R)-RvD1 (300 and 900 ng/kg) in rats with surgically induced ENDO.

Main Outcome Measure(s):

Vascular permeability of ectopic endometrial growths was assessed by Evans Blue extravasation; vaginal hyperalgesia was assessed with telemetered visceromotor response.


Both resolvins, but not vehicle, significantly decreased vascular permeability in ectopic endometrial tissue. 17(R)-RvD1 also significantly alleviated severity of vaginal hyperalgesia.


Our results suggest that RvD1 and 17(R)-RvD1 can be considered for further investigation of their therapeutic potential for treating ENDO.

Read the full text at:

Please sign in or register for FREE

Your Fertility and Sterility Dialog login information is not the same as your ASRM or EES credentials. Users must create a separate account to comment or interact on the Dialog.